Payment overview · 2025
General Payments
$897.23
40 reported records · 11 companies
Healthcare provider profile · identity verified
Gordon Thacker Connor, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BIRMINGHAM, AL · NPI 1801804703
Verified facts
What the public records show
CMS Open Payments records show Gordon Thacker Connor, MD received $897.23 in general payments during 2025 across 40 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $321.66 | 35.9% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $213.91 | 23.8% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $94.79 | 10.6% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $61.82 | 6.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.19 | 6.6% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $40.36 | 4.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.91 | 2.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.38 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.14 | 2.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.84 | 2.3% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $19.23 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $897.23 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $259.54 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $213.91 | 11 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $94.79 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $66.42 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $61.82 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $43.63 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.63 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $40.36 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 194 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 73 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 119 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
119 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
194 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 952 | 252 |
| Amlodipine Besylate | Amlodipine Besylate | 781 | 220 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 511 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 473 | 136 |
| Gabapentin | Gabapentin | 425 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 425 | 109 |
| Irbesartan | Irbesartan | 387 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 348 | 86 |
| Hydrochlorothiazide | Hydrochlorothiazide | 328 | 101 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 328 | 44 |
| Mounjaro | Tirzepatide | 326 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 323 | 79 |
| Tizanidine Hcl | Tizanidine Hcl | 319 | 83 |
| Carvedilol | Carvedilol | 316 | 75 |
| Metformin Hcl Er | Metformin Hcl | 298 | 83 |
| Lisinopril | Lisinopril | 288 | 80 |
| Montelukast Sodium | Montelukast Sodium | 288 | 75 |
| Tramadol Hcl | Tramadol Hcl | 276 | 42 |
| Trulicity | Dulaglutide | 267 | 40 |
| Omeprazole | Omeprazole | 252 | 64 |
| Spironolactone | Spironolactone | 220 | 64 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 213 | 60 |
| Jardiance | Empagliflozin | 201 | 44 |
| Eliquis | Apixaban | 194 | 46 |
| Metformin Hcl | Metformin Hcl | 186 | 61 |
| Potassium Chloride | Potassium Chloride | 182 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 177 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 176 | 70 |
| Azelastine Hcl | Azelastine Hcl | 175 | 73 |
| Memantine Hcl | Memantine Hcl | 171 | 32 |
| Losartan Potassium | Losartan Potassium | 169 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 164 | 49 |
| Allopurinol | Allopurinol | 161 | 43 |
| Hydralazine Hcl | Hydralazine Hcl | 158 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 35 |
| Furosemide | Furosemide | 141 | 44 |
| Temazepam | Temazepam | 139 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 41 |
| Topiramate | Topiramate | 124 | 40 |
| Trazodone Hcl | Trazodone Hcl | 119 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 119 | 29 |
| Doxazosin Mesylate | Doxazosin Mesylate | 118 | 33 |
| Pregabalin | Pregabalin | 117 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 18 |
| Clonazepam | Clonazepam | 114 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 110 | 24 |
| Torsemide | Torsemide | 107 | 43 |
| Benazepril Hcl | Benazepril Hcl | 105 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 27 |
| Verapamil Er | Verapamil Hcl | 104 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 30 |
| Cefuroxime | Cefuroxime Axetil | 99 | 83 |
| Sertraline Hcl | Sertraline Hcl | 99 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 93 | 25 |
| Sucralfate | Sucralfate | 93 | 27 |
| Famotidine | Famotidine | 90 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 89 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 84 | 23 |
| Diazepam | Diazepam | 83 | 13 |
| Ramipril | Ramipril | 81 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 79 | 26 |
| Ezetimibe | Ezetimibe | 79 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 27 |
| Donepezil Hcl | Donepezil Hcl | 77 | 20 |
| Ozempic | Semaglutide | 77 | 15 |
| Celecoxib | Celecoxib | 76 | 28 |
| Bupropion Xl | Bupropion Hcl | 75 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 75 | 21 |
| Farxiga | Dapagliflozin Propanediol | 73 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 20 |
| Alendronate Sodium | Alendronate Sodium | 71 | 21 |
| Mirtazapine | Mirtazapine | 71 | 27 |
| Glipizide | Glipizide | 67 | 18 |
| Alprazolam | Alprazolam | 65 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 64 | 13 |
| Baclofen | Baclofen | 60 | 15 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 60 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 16 |
| Nystatin | Nystatin | 58 | 27 |
| Clonidine Hcl | Clonidine Hcl | 55 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | suppressed |
| Simvastatin | Simvastatin | 54 | suppressed |
| Linzess | Linaclotide | 53 | 11 |
| Buspirone Hcl | Buspirone Hcl | 52 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 13 |
| Meloxicam | Meloxicam | 47 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | 15 |
| Fluconazole | Fluconazole | 45 | 28 |
| Synthroid | Levothyroxine Sodium | 45 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 14 |
| Atenolol | Atenolol | 44 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | suppressed |
| Ibuprofen | Ibuprofen | 43 | 12 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 43 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 11 |
| Valsartan | Valsartan | 41 | 12 |
| Digoxin | Digoxin | 39 | suppressed |
| Glimepiride | Glimepiride | 38 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 14 |
| Metolazone | Metolazone | 37 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 12 |
| Lansoprazole | Lansoprazole | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Prednisone | Prednisone | 34 | 13 |
| Lidocaine | Lidocaine | 32 | 12 |
| Clonidine | Clonidine | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Azithromycin | Azithromycin | 29 | 19 |
| Eplerenone | Eplerenone | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 16 |
| Estradiol | Estradiol | 27 | 12 |
| Meclizine Hcl | Meclizine Hcl | 27 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 23 |
| Colchicine | Colchicine | 26 | 11 |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Methocarbamol | Methocarbamol | 25 | 11 |
| Naproxen | Naproxen | 25 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Nateglinide | Nateglinide | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Verapamil Sr | Verapamil Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 18 |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 16 |
| Lactulose | Lactulose | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 11 |
| Levofloxacin | Levofloxacin | 17 | 16 |
| Metronidazole | Metronidazole | 17 | 13 |
| Olanzapine | Olanzapine | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Benicar | Olmesartan Medoxomil | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $897.23 · 40 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Dexcom G6 Transmitter, Dyanavel XR, ELIQUIS, FARXIGA, FREESTYLE LIBRE, Korlym, NURTEC ODT, QULIPTA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error